An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue SUPPL.2, 2011, Pages 13-21

  Chang, John Wen Cheng ^a   Thongprasert, Sumitra ^b   Wright, Elaine ^j   Tsang, Kenneth ^c,d   Kim, Heung Tae ^e   Ahn, Myung Ju ^f   Kim, Joo Hang ^g   Kang, Jin Hyoung ^h   Kim, Sang We ⁱ   Walzer, Stefan ^j  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c Queen Mary Hospital ^*

^d QUEEN MARY HOSPITAL   (Hong Kong)

^e National Cancer Center   (South Korea)

^f Samsung Medical Center   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h The Catholic University of Korea   (South Korea)

ⁱ University of Ulsan College of Medicine   (South Korea)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

Antineoplastic combined chemotherapy protocols; Asia; Bevacizumab; Effectiveness; Non small cell lung carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BEVACIZUMAB PLUS CISPLATIN; CISPLATIN; CISPLATIN PLUS PEMETREXED; GEMCITABINE; PEMETREXED; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SQUAMOUS NON SMALL CELL LUNG CANCER; NON SQUMAOUS NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TREATMENT OUTCOME;

EID: 79956069755     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01398.x     Document Type: Article

References (31)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, Lyons, France 2010 [cited 14 April 2011]. Available from: .
2. Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009; 4: 1083-93.
3. Kawaguchi T, Matsumura A, Fukai S etal. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010; 5: 1001-10.
4. Ahn MJ, Lee J, Park YH etal. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. J Thorac Oncol 2010; 5: 1185-96.
5. Saijo N, Fukuoka M, Thongprasert S etal. Lung Cancer Working Group report. Jpn J Clin Oncol 2010; 40: i7-12.
6. Saijo N, Takeuchi M, Kunitoh H. Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nat Rev Clin Oncol 2009; 6: 287-94.
7. NCCN Non-Small Cell Lung Cancer USA. NCCN clinical practice guidelines in oncology: non-small cell lung cancer V.3.2011. National Comprehensive Cancer Network. 2011 [cited 14 April 2011] .Available from: .
8. Bevacizumab - cancer drug information. National Cancer Institute USA. 2011 [cited 3 January 2011.] Available from: .
9. Eichhorn M, Kleespies A, Angele MK, Jauch K, Bruns C. Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg 2007; 392: 371-9.
10. Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov 2007; 2: 59-71.
11. Reck M, von PJ, Zatloukal P etal. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34.
12. Reck M, von Pawel J, Zatloukal P etal. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21: 1804-9.
13. Sandler A, Gray R, Perry MC etal. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
14. Scagliotti GV, Parikh P, von PJ etal. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
15. Mok T, Hsia T-C, Tsai C-M etal. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial. Asia-Pac J Clin Oncol 2011; 7(Suppl. 2): 4-12.
16. Yang CH, Simms L, Park K, Lee JS, Scagliotti G, Orlando M. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. J Thorac Oncol 2010; 5: 688-95.
17. Nuijten M, Heigener DF, Bischoff HG etal. Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 2010; 69: S4-S10.
18. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-91.
19. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326: 472-7.
20. Glenny AM, Altman DG, Song F etal. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9: 1-iv.
21. Gartlehner G, Moore CG. Direct versus indirect comparison: a summary of the evidence. Int J Technol Assess Health Care 2008; 24: 170-7.
22. Schiller JH, Harrington D, Belani CP etal. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
23. Silvestrini, R. Basi Scientifiche Linea Guida: Carcinoma Non a Piccole Cellule [in Italian]. [Internet]. Instituto Superiore di Sanità (ISS) ©- Aleanza Contro il Cancro 2011 [cited 3 Jan 2011.] Available from:
24. Department of Health and Ageing. Australian public assessment report for bevacizumab. Therapeutic Goods Administration, Australian Government, Canberra, 2010 [cited 14 April 2011]. Available from .
25. Goeckenjan G, Sitter H, Thomas M etal. Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 2011; 65: 39-59.
26. L'Institut National du Cancer. Recommandations professionnelles: Cancer du poumon non à petites cellules. INCa, Boulogne-Billancourt 2010.
27. Oxford Centre for Evidence-based Medicine. Levels of evidence (March 2009). 2011 [cited 11 February 2011.] Available from: .
28. Department of Health and Ageing. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 4.3) 2008. 2008. Therapeutic Goods Administration, Australian Government [cited 14 April 2011]. Available from: .
29. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa 2009.
30. National Institute for Health and Clinical Excellence. Pemetrexed for the first-line treatment of non-small-cell lung cancer [TA181]. 2009. Report No: TA181.
31. Chang G-C, Ahn M-J, Wright E etal. Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real life outcomes. Asia-Pac J Clin Oncol 2011; 7(Suppl. 2): 34-40.